Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Samsung to invest $10 million in US-based C2N Diagnostics
Samsung Group companies will jointly invest $10 million in C2N Diagnostics LLC, a U.S.-based company specializing in blood-based Alzheimer’s d...
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Celltrion obtains approval of Steqeyma from FDA
South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...
Celltrion releases Steqeyma in Europe
South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...
Celltrion's Zymfentra gets 90% distribution channel in US
South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...
IMBiologics transfers autoimmune disease drug tech to Huadong Pharma
South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...
Costco sells Celltrion's Yuflyma Low WAC in US
South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...
Celltrion gets approval of Steqeyma in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...
Celltrion to supply Remsima, Herzuma to Peru
South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...
Samsung Bioepis gets OK to sell Stelara biosimilar in Europe
South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...
Celltrion releases Remsima SC in Denmark
South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...
Samsung begins new drug development for rare diseases
Samsung Bioepis Co., a biosimilar development unit of South Korea’s top conglomerate Samsung Group, has begun its new drug development busines...
Reversing age possible in a decade: Harvard Prof. David Sinclair
Humans will be able to control biological age and reverse their age in 10 years with advancements in medical science and live up to around 120, abou...
Celltrion'a autoimmune disease drug Zymfentra makes US debut
South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...
Celltrion ships initial supply of Zymfentra to US
South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...
Kakao Brain releases medical GenAI tech for free
Kakao Brain, an artificial intelligence (AI) R&D subsidiary of South Korea's Kakao Corp., announced on Tuesday that it has uploaded the Labeler ...
Celltrion to supply Remsima SC, Yuflyma to Norway
South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...
Kakao launches AI-based blood sugar management solution
South Korea’s Kakao Healthcare Corp. has introduced an artificial intelligence-based blood sugar management solution targeting the global digi...
ToolGen gets FDA approval for TGT-001 as ODD
South Korean genome editing developer ToolGen Inc. announced on Monday that its application for orphan drug designation (ODD) of the gene correction...
SK C&C to promote AI healthcare for brain diseases
South Korea's SK C&C announced on Thursday that it signed a strategic business agreement with Neurophet, a cloud-based AI platform for brain ima...
Dong-A ST, UMass to jointly research for gene therapy
South Korea's Dong-A ST announced on Friday it has signed a joint research agreement with the University of Massachusetts (UMass) Chan Medical Schoo...
Naver-invested ichrogene enters Thai market
South Korea's digital healthcare startup ichrogene, with investment from Naver D2 Startup Factory (D2SF), entered into Thai market. Naver Corp....
Celltrion gets FDA approval for Remsima SC
South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient i...
Celltrion Healthcare wins Remsima order in France, Italy
South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for ho...
S.Korean vaccine developer Quratis eyes Iraqi market
South Korean vaccine developer Quratis Inc. on Wednesday announced its signing of a term sheet on the direction and major transaction terms of coope...
NGeneBio applies for US patent of early diagnosis tech of dementia
South Korean medical diagnostic company NGeneBio Co. announced on Thursday that it has completed the US patent application for its technology relate...
VaxCell Bio's treatment shows promise for advanced liver cancer
South Korea's VaxCell Biotherapeutics Co. on Tuesday said its treatment for advanced liver cancer under development stopped or greatly reduced the g...
Samsung Bioepis to cooperate with Swiss firm Sandoz
Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, announced on Monday that it signed a partn...
Yungjin Pharm's new drug candidate gets Fast Track from FDA
South Korea's Yungjin Pharm has secured Fast Track designation from the US Food and Drug Administration (FDA) for its new drug candidate KL1333, des...
